Q3 2026 payor earnings: three questions for healthcare leaders

a pair of glasses resting on a stack of books
Summary: Explore three Q3 2026 payor earnings takeaways on vertical integration, self-funded plans, and prior authorization — and what they mean for health systems.

CVS Health’s planned breakup dominated the Q3 2026 payor earnings cycle, but it wasn’t the only development with consequences for hospitals and health systems. Payors reported shifting membership, made different bets on where to grow, and announced changes to prior authorization. Behind those results are three questions that should inform how providers approach payor strategy and contract negotiations.

1. What is the future of vertical integration?

The biggest news of the quarter was CVS Health’s plan to separate into two publicly traded companies by 2028. The proposed healthcare solutions company would retain Aetna, CVS Caremark, CVS Specialty, Oak Street Health, and Signify Health. The retail company would include approximately 9,000 CVS pharmacies, mail pharmacy operations, MinuteClinic, and Health100.

CVS says the move will give each company greater strategic focus and financial flexibility. I doubt the company would have made this decision without the growing scrutiny of vertically integrated healthcare businesses. State pharmacy associations and lawmakers have challenged the relationship between PBMs and affiliated pharmacies, and CVS has fought state laws restricting those ownership arrangements.

The planned separation would put the retail pharmacy chain under different ownership from Aetna and Caremark. That responds to one area of regulatory concern, including laws in states such as Tennessee that restrict common ownership of PBMs and pharmacies. But CVS Specialty would remain with Aetna and Caremark, so the separation doesn’t eliminate common ownership of insurance, pharmacy benefits, and pharmacy services.

CVS would also retain its care delivery businesses. The resulting healthcare company would still have a combination of insurance, pharmacy benefits, specialty pharmacy, and care delivery that allows it to compete with other integrated payors. UnitedHealth Group has UnitedHealthcare and Optum. Elevance has Health Benefits and Carelon. Cigna has Cigna Healthcare and Evernorth. Each is structured differently, but each has capabilities beyond insurance.

That combination remains a target for lawmakers. Bipartisan legislation introduced in Congress would restrict common ownership of insurers or PBMs and pharmacies, including specialty pharmacies. If Congress enacted a restriction like that, CVS could face further restructuring even after the planned separation, and this time they’d be joined by other major payors. The larger question is, if you can’t employ the pharmacist, own the pharmacy, and own the PBM, then why can you employ the doctor and own the medical benefit/insurance company?

2. Which risks do payors want to carry?

The membership shifts we saw in Q2 continued, but payors are making different choices about where they want to grow and what financial risk they want to assume.

UnitedHealth Group reported higher operating earnings while covering nearly 1.5 million fewer people than at the beginning of 2026. Elevance’s Medicare Advantage and Medicaid membership declined year over year, while Centene had 2.27 million fewer at-risk members than a year ago, including substantial declines in Commercial and Medicaid.

Some of those changes reflect deliberate decisions about pricing, products, and markets. Others reflect eligibility changes, competition, or customer transitions. They don’t all tell the same story.

At the same time, administrative-services membership grew. Elevance added 603,000 commercial fee-based members, bringing that population to 27.6 million — more than 61% of its medical membership. Cigna’s U.S. administrative-services-only membership grew by 500,000 over the past year, while its U.S. insured membership fell by 153,000.

Those arrangements allow payors to earn fees for administering coverage while plan sponsors generally retain the underlying medical claims risk. They also bring more decision-makers into the picture for providers. It may also bring in a third party to manage high-cost or high-utilization benefits. Those decisions can affect patient access, steer services away from your organization, and add administrative requirements — even when your contract with the payor hasn’t changed.

Health systems should understand how much of their commercial membership is covered through self-funded plans and which plan sponsors and third-party vendors influence those patients’ benefits. Where are benefit designs or vendor requirements changing referral patterns, access, reimbursement, or administrative work? Are your contracts giving you the information and protections you need when those arrangements change?

3. How much work will prior authorization reform actually remove?

UnitedHealth and Centene probably expected their prior authorization announcements to earn them some positive attention this quarter. But they should be met with a healthy dose of skepticism. If prior authorization is really as important to reining in healthcare costs as payors say it is, then how can UnitedHealth eliminate 30% of their prior authorization list? Or is this a confirmation of what the overturn rate of denials has already told us? Prior authorization adds unnecessary barriers between patients and care and huge amounts of administrative burdens on providers throughout the country.

Centene announced a Gold Card program for qualifying providers under which selected outpatient services will require notification rather than a traditional authorization determination. Providers must still submit a notification before delivering care, so the administrative process has changed rather than disappeared. And I’m curious about whether we’ll see an uptick in the volume of retrospective reviews and denials since there was no authorization.

Payors should show providers what changes across the entire process. How much staff time does notification require? Are patients getting scheduled sooner? Are claims paid promptly, or do retrospective reviews and denials create more work after care has been delivered?

For health systems, the task is to measure those results alongside the number of authorizations removed. If work shifts from the front end to the back end, providers and patients may see less relief than the announcements suggest. And ultimately, do you care if authorizations go away if denials increase?

What this means for providers

Payors are making deliberate decisions about which businesses to own, which populations to cover, and how much risk to carry. Health systems need to understand how those decisions affect each contract and each patient population.

Look at performance by payor, product, and plan: the reimbursement received, the services provided, the administrative work required, and the patient balances left to collect. Understand where the payor wants to grow, where it has its own care-delivery or pharmacy assets, and where it depends on your organization’s access, specialties, physicians, or reputation. Don’t lend your brand and reputation to products or plans that are not good for the patient or your organization.

Then carry those findings into negotiations. Rates matter, but so do specialty pharmacy terms, site-of-care requirements, notification rules, denials, payment timelines, and the cost of administering the agreement.

Author photo

About Kevin

Kevin currently serves as the Chief Managed Care Officer and Chief Revenue Strategy Officer of Unlock Health. He leads the managed care, value-based care, communications and reimbursement strategy/transformation practices as well as sits on the advisory councils for new strategic investments for the firm.

Share this blog:

Related Resources